-
PNAS: New study reveals that IL-6 signal blocking therapy can be effective in treating severe neo-crown pneumonia.
Time of Update: 2020-09-27
study of cytokine spectrum in patients with severe COVID-19 found that IL-6 increased in the early stages of the disease, leading to the release of PAI-1 from blood vessels," said Tadamitsu Kishimoto of Osaka University, co-author of the paper.
-
Cell: A rare inflammatory reaction occurs in children with COVID19.
Time of Update: 2020-09-27
"Our results show that while MIS-C has some common characteristics, it is indeed a very different inflammatory disease from Kawasaki disease," said Peter Brodin, a pediatrician and researcher in the Department of Women's and Children's Health at the Karolinska Institute.
-
NEJM: Studies have revealed that COVID19 infection produces long-term protective body fluid immunity.
Time of Update: 2020-09-27
, however, the Icelandic study offers hope that a vaccine that triggers a strong immune response will have a more lasting effect than some believe.
(bioon.com) Source: Antibody study suggests more lasting immunity against COVID than believed Daniel F.
-
Cell Death and Dis: Special proteins may contribute to the worsening of breast cancer.
Time of Update: 2020-09-26
September 14, 2020 // -- Scientists from the University of Alberta and others have been working on a protein directly related to poor prognostication in breast cancer patients, and since then they hav
-
Nat Immunol: There is persistent T-cell immune protection in patients recovering from COVID19.
Time of Update: 2020-09-26
" Although the team believes that poor T-cell response may lead to persistence of SARS-CoV-2 virus and COVID-19 mortality, recovering patients with mild and severe diseases still have T-cell memory two months after infection.
-
Mol Cell: For the first time, a complete image of all communication paths in human cells infected with SARS-CoV-2 is expected to help develop a new type of targeted COVID-19 therapy.
Time of Update: 2020-09-26
researcher Christian Münch explains that the growth factor's signaling pathline can be precisely blocked at a certain point, i.e. when the extracellular signal reaches the growth factor recipient signaling receiver, however, there are some very effective cancer drugs that slightly block the growth factor signaling path in the cascading reaction, through which different growth factor recipient signals are blocked, and now researchers have tested five of these substances in the cells, which are perfectly capable of blocking SARS-CoV-2 replication.
-
JAMA Network Open: Vitamin D deficiency in the body may increase an individual's risk of COVID-19.
Time of Update: 2020-09-26
Photo Source: David Meltzer, M.D., CC0 Public Domain, says vitamin D plays a vital role in the body's immune system, after previous studies have shown that vitamin D supplements may be effective in reducing the risk of respiratory viral infections, and statistical analysis in this paper suggests that vitamin D supplementation may be promising to treat SARS-CoV-2 infections.
-
Nature: Tumor cells are better at "grabbing" nutrients than T cells.
Time of Update: 2020-09-26
September 2, 2020, nature published online the University of Michigan study "Cancer SLC43A2 Alters T cell methionine metabolism and histonemethylation", which details how tumor cells alter T-cell methionine metabolism and histone methylation through the solute vector SLC43A2, revealing the new mechanisms of tumor immune escape.
-
Breakthrough drug for cholestasis! Phase III of the potent ileal bile acid transporter inhibitor odevixibat succeeded: reaching the European and American regulatory endpoint!
Time of Update: 2020-09-26
results showed that the study reached two main endpoints: odevixibat significantly reduced bile acid response (SBA, p-0.003), significantly improved skin itching (p-0.004), and had a single-digit diarrhea rate compared to placebo.
-
EJPS: Researchers have developed new anti-inflammatory drugs.
Time of Update: 2020-09-26
SEPTEMBER 11, 2020 /--- In a recent study, Halle-Wittenberg, a researcher at Martin LutherAne University's Institute of Pharmaceuticals, et al., developed a method for producing controlled-quality anti-inflammatory drugs.
show that phospholipids work well in anti-inflammatory treatments, " said Mäder, a research team.
-
PNAS: Split immunotoxins in two or hopefully kill cancer cells with precision without damaging the function of healthy cells.
Time of Update: 2020-09-26
14, 2020 // -- In a recent study published in the international journal PNAS, scientists from Ohio State University and other institutions found that spliting an anticancer drug in two and then giving
-
Sci Trans Med: A breakthrough in gene therapy.
Time of Update: 2020-09-26
-related virus 2 (AAV2) is a viral vector that acts as a carrier for carrying therapeutic DNA to target cells in the body in specific gene therapies.
-
Innovative drug for optic neurospinal corditis spectrum disorder (NMOSD)! Roche IL-6R monoantigen-resistant Enspryng significantly reduces the severity and risk of recurrence!
Time of Update: 2020-09-26
this effect was more pronounced in sero-positive patients with water channel protein-4 antibodies (AQP4-IgG), who had a more severe course of disease and a 66% lower risk of recurrence (HR-0.34; 95% CI:0.19-0.62; p-lt;0.001) compared to the placebo group.
-
New anti-inflammatory drugs! Sanofi/Regenerative Dupixent (Dabito®) significantly delays lung function decline in asthma patients: the efficacy is maintained for 3 years!
Time of Update: 2020-09-26
The results presented at the ERS conference were as follows: - Efficacy data: (1) Lung function: Patients continued to improve lung function by 13-22% during 96 weeks of treatment, as measured by an average change in maximum force exhalation capacity (FEV1) in the first second compared to the baseline of the initial asthma trial.
-
Breakthrough drugs for cystic fibrosis (CF)! Vertex's innovative triple therapy Trikafta treatment for children aged 6-11 years has been successful in Phase 3 research!
Time of Update: 2020-09-26
October 2019, Trikafta was approved by the FDA to treat at least one patient with an F508del mutation in the cystic fibrosis transfilm conduction regulatory factor (CFTR) gene, with a age of 12 years, in patients with 2 F508del mutations (F/F), or one patient with an F508del mutation and one minimum functional mutation (F/MF).
-
NEJM: Phase 1-2 clinical trials have shown that the NVX-CoV2373 candidate vaccine is safe and induces a strong immune response.
Time of Update: 2020-09-26
study was recently published in the journal NEJM under the title "Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine".
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.
-
15-price pneumonia vaccine! Mercedon V114 two Adult III studies were successful: submit a listing application at the end of the year!
Time of Update: 2020-09-26
In June this year, two other adult Phase III studies of V114 also met safety and immunogenicity goals: (1) the PNEU-WAY (W114-08) study was conducted in adults 18 years of age and older infected with HIV, and the results showed that V114 produced immune responses to all 15 serotypes in the vaccine, including serotypes 22F and 33F.
-
PLOS BIOLOGY: Delayed immune response makes older men more susceptible to COVID19.
Time of Update: 2020-09-26
study published On September 8, 2020 in the open-access journal PLOS Biology, Nicole Lieberman and Alexander Greninger of the University of Washington and colleagues found that different immune responses to SARS-CoV-2 may depend on viral load and the timing of infection, depending on age and gender.
-
Nat Cell Biol: What's new! Cells with lower "stickiness" may be more prone to cancer!
Time of Update: 2020-09-26
10, 2020 // -- In a recent study published in the international journal Nature Cell Biology, scientists from the University of Leipzig and others analyzed in detail the structure of tumor tissue and the behavioral characteristics of tumor cells, and the results may help improve cancer diagnosis and the development of future targeted cancer therapies.
-
Immunity: Allergic reactions help fight bacterial infections.
Time of Update: 2020-09-26
the bacteria is a prototype antibiotic-resistant pathogen and has been linked to the development of allergic immune responses in diseases such as asthma and endexual dermatitis.
found that mice with mild Staphylococcus austratic skin infections produced adaptive immune responses and specific IgE antibodies to bacterial components.
